Alzheimer’s disease is the most common dementia affecting
millions of Americans. It impacts many
of our clients as well. Those suffering
with it now are using a number of medications, most of which have been in use
for several years. There is a need for
new medical treatments to manage and hopefully someday eliminate this disease. The process of developing these new medications
can take years of research and clinical trials.
Visiting Angels is pleased to announce we are giving referrals for
clinical trials for investigational medications to treat Alzheimer’s disease in
association with Donald S. Marks, MD, a Board Certified Neurologist, specialist
in Alzheimer’s disease and an Assistant Clinical Professor at Tufts.
We are currently seeking participants for a very
important study. Enrollment in this
Phase 3 clinical trial is in progress.
By participating in the clinical trial, participants will be part of an
effort that may help them improve their mental function. In addition, participants will provide valuable data that
may help others in the future.
To be eligible to participate in the study participants
should have a diagnosis of mild to moderate Alzheimer’s disease, have
previously been on or are currently on a stable dose of Aricept (donepezil),
Exelon (rivastigmine), or Razadyne (Galantamine) and be between the ages of 55
and 85. Participants who are taking
Namenda (memantine) are not appropriate for the study.
If you or the person you care for would like to
participate in this clinical trial please contact Nate Murray at 781-834-6355 extension 12. He can give you further information and begin
the process of coordinating your introduction to Dr. Marks.
No comments:
Post a Comment